| Literature DB >> 34366889 |
Abstract
Resistance arteries and downstream arterioles in the peripheral microcirculation contribute substantially to peripheral vascular resistance, control of blood pressure, the distribution of blood flow to and within tissues, capillary pressure, and microvascular fluid exchange. A hall-mark feature of these vessels is myogenic tone. This pressure-induced, steady-state level of vascular smooth muscle activity maintains arteriolar and resistance artery internal diameter at 50-80% of their maximum passive diameter providing these vessels with the ability to dilate, reducing vascular resistance, and increasing blood flow, or constrict to produce the opposite effect. Despite the central importance of resistance artery and arteriolar myogenic tone in cardiovascular physiology and pathophysiology, our understanding of signaling pathways underlying this key microvascular property remains incomplete. This brief review will present our current understanding of the multiple mechanisms that appear to underlie myogenic tone, including the roles played by G-protein-coupled receptors, a variety of ion channels, and several kinases that have been linked to pressure-induced, steady-state activity of vascular smooth muscle cells (VSMCs) in the wall of resistance arteries and arterioles. Emphasis will be placed on the portions of the signaling pathways underlying myogenic tone for which there is lack of consensus in the literature and areas where our understanding is clearly incomplete.Entities:
Keywords: G-proteins; arterioles; ion channels; mechanotransduction; myogenic tone; resistance arteries
Year: 2021 PMID: 34366889 PMCID: PMC8339585 DOI: 10.3389/fphys.2021.699517
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Figure 1The myogenic response and myogenic tone in arterioles. (A) Myogenic response in a cannulated hamster cremaster arteriole, ex vivo, prepared as described (Westcott and Jackson, 2011). Shown in the upper panel is a digitized diameter record of the response of a second-order cremaster arteriole to a step-increase in luminal pressure from 20 to 80 cm H2O as depicted in the lower panel. At the onset of the pressure step, arteriolar diameter increases due to passive distention of the vessel. As the smooth muscle responds and begins to contract, diameter recovers to a new steady-state diameter that is slightly less than the diameter at 20 cm H2O. This behavior is the myogenic response. (B) Myogenic tone in cannulated hamster cremaster arterioles. Top panel shows the steady-state diameters of arterioles at different pressures in the absence of extracellular Ca2+ (passive) and presence of 2 mM Ca2+ (active). Bottom panel shows the % myogenic tone at the given pressures computed from the data in the top panel as myogenic tone = (passive diameter–active diameter)/passive diameter × 100%. At pressures greater than 20 cm H2O, arterioles develop significant myogenic tone (i.e., steady-state pressure-induced constriction). Data in (A) are replotted from Jackson (2012), with permission. Data in (B) are replotted from Westcott and Jackson, (2011) and Jackson, (2012), with permission.
Figure 2Signaling pathways for pressure-induced myogenic tone. Schematic diagram of reported signaling pathways involved in myogenic tone in resistance arteries and arterioles. Green font color depicts putative mechanosensors in pressure-induced myogenic tone. Black arrows show stimulation, increases or activation of signaling molecules, ion channels, or enzymes that participate in myogenic tone. Red capped lines indicate inhibition, decreases or deactivation of signaling molecules, ion channels, or enzymes involved in myogenic tone. Also shown are pharmacological agents that we have used to interrogate the ion channels and signaling pathways in arteriolar myogenic tone. MMP, matrix metalloproteinase; HB-EGF, heparin-bound epidermal growth factor; EGFR, epidermal growth factor receptor; ERK1/2, extracellular-signal-related kinases 1 or 2; JAK, janus kinase; STAT3, signal transducer and activator of transcription 3; mTNFα, membrane-bound tumor necrosis factor α; TNFR, TNFα Receptor; S1P, sphingosine-1-phosphate; S1PR, S1P receptor; α5β1-int, α5β1 integrin: FAK, focal adhesion kinase; SRK, Src-related kinases; CaCC, Ca2+-activated Cl− channel; TRPV2,4, transient receptor potential vanilloid-family 2 or 4 channels; ENaC, epithelial Na+ channel; ASIC, acid sensing ion channel; P2X7, P2X7 purinergic receptor; VGCC, voltage-gated Ca2+ channel; BKCa, large-conductance Ca2+-activated K+ channel; KV, voltage-gated K+ channel; KIR, inwardly-rectifying K+ channel; KATP, ATP-sensitive K+ channel; msGPCR, mechanosensitive G-protein-coupled receptor; DAG, diacylglycerol; PKC, protein kinase C; NFA, niflumic acid; DTZM, diltiazem; NIF, nifedipine; TEA, tetraethylammonium; IBTX, iberiotoxin; 4-AP, 4-aminopyridine; GLIB, glibenclamide; BIM I, bisindolylmaleimide I; PLC, phospholipase C; PIP2, phosphatidylinositol bisphosphate; IP3, inositol, 1,4,5 trisphosphate; IP3R1, IP3 receptor 1; RyR, ryanodine receptor; CICR, Ca2+-induced-Ca2+ release; LARG, guanine nucleotide exchange factor LARG; RhoA, small G-protein Rho; 2-APB, 2-Aminoethoxydiphenyl borate; RhoK. Rho kinase; LIMK, LIM kinase; CPI17, C-kinase potentiated protein phosphatase-1 Inhibitor; MLCPPT, myosin light-chain phosphatase; MCL, myosin light-chain; MLCK, myosin light-chain kinase; See text for more details and references.